Siemens Healthineers Q1 sales beat expectations on strong Varian unit
Reuters
Published Feb 01, 2024 06:26
BERLIN (Reuters) - German medical equipment maker Siemens Healthineers on Thursday posted first-quarter revenue above expectations and an operating result in line with consensus, driven by its U.S. cancer treatment unit Varian.
It said Varian's revenue improved most in China after sales had been affected by supply chain delays in the prior-year period.
Adjusted earnings before interest and taxes (EBIT) reached 742 million euros ($802 million) in the three months through December on revenue of 5.18 billion, the group said.
Analysts had expected quarterly adjusted EBIT of 742 million euros on revenue of 5.11 billion, according to a company-provided poll.
The company's diagnostics unit, which encompasses its laboratory testing and includes the now-ended COVID-19-test business, saw its quarterly revenue fall 7.7% in the first quarter.
Siemens Healthineers confirmed its 2024 guidance and still expects adjusted basic earnings per share to be between 2.10 and 2.30 euros and comparable revenue growth of between 4.5% to 6.5%.
($1 = 0.9257 euros)
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.